You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: paroxetine and placebo do not differ for treatment discontinuation in major depression

https://doi.org/10.1136/ebm.13.4.110

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    C Barbui

    Dr C Barbui, University of Verona, Verona, Italy; corrado.barbui@univr.it

    QUESTION

    In participants with major depression, what is the effectiveness and acceptability of paroxetine?

    REVIEW SCOPE

    Included studies compared any flexible- or fixed-dose (⩾20 mg/d) regimen of any pharmaceutical form of paroxetine with placebo in participants ⩾18 years of age with major depression. Outcomes included treatment discontinuation, depression, <50% improvement in symptoms, adverse events, and suicidal tendencies.

    REVIEW METHODS

    Medline; EMBASE/Excerpta Medica; Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials Register; Cochrane Central Register of Controlled Trials; and Glaxo-SmithKline Clinical Trial Register (all to December 2006) were searched for published and unpublished randomised placebo controlled trials (RCTs). 29 published RCTs and 11 unpublished RCTs (n = 6391) were included in …

    View Full Text

    Footnotes

    • Source of funding: Japanese Ministry of Education, Science and Technology and Japanese Ministry of Health Labour and Welfare.